Adial Pharmaceuticals Inc. (NASDAQ: ADIL) Announce Positive PNV2 Data in Triple-Negative Breast Cancer

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has announced promising pre-clinical results for PNV2 in animal models for triple-negative breast cancer. Based on these results, the company’s wholly-owned subsidiary Adial Pharmaceuticals will now advance PNV2 as a flagship compound for its cancer program.

Pre-clinical data show a reduction of metastases 

PNV2 was studied in a metastatic breast cancer model, with the primary endpoint being the number of cancer metastases in the lungs 28 days after orthotopic breast cancer implantation.

Purnovates VP research Dr. Julien Dimastromatteo stated, “This pre-clinical data is encouraging, as we seem to have demonstrated a reduction in metastases and cancer invasion into the lungs following treatment with PNV2. This data confirms prior research on the anti-cancer properties of adenosine analogs. However, historically, the solubility of these compounds has been a barrier to developing an effective therapy. This latest research around PNV2 is particularly exciting as we believe we have overcome the solubility challenges. We plan to conduct additional pre-clinical research with a goal of advancing PNV2 into clinical trials in 2022.”

CEO of Adial William Stilley said, “The Purnovate adenosine platform continues to demonstrate broad potential across a wide range of indications and is exceeding expectations. We are especially encouraged by this latest data in triple negative breast cancer following the recent pain data. We look forward to aggressively pursuing the full potential of the Purnovate Adenosine Platform and are evaluating the best strategy to achieve full value for our shareholders from the Platform, while we remain laser focused at Adial on obtaining our Phase 3 data on AD04 for treatment of Alcohol Use Disorder.”

PNV2 is more selective relative to Adenosine A1 receptor 

PNV2 has been shown to be more than 1000-fold selective over the adenosine A1 receptor linked to cardiovascular and CNS side effects, limiting the use of adenosine analogs as therapies. Notably, when selectivity over the A1 receptor has been achieved in the past, water solubility diminished, making effective tissue distribution in the human body challenge. On the other hand, PNV2 has a more than 50 times solubility relative to other selective adenosine compounds in the same class.